- Price
- $239.56
- Day
- -2.42%
- Mkt Cap
- $32.06B
- 52W Range
- $197.81 – $495.55
- Volume
- 2.76M
- Beta
- 0.30
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Alnylam Pharmaceuticals (NASDAQ: ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook. Speaking at the Morgan Stanley Global Healthcare Conference, Chief Executive Officer Yvonne Greenstreet said Alnylam's TTR franchise
Read full article
Alnylam Pharmaceuticals (NASDAQ: ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. During an RNAi Roundtable, executives and clinical speakers emphasized the global burden of hypertension, challenges with adherence to daily oral therapies
Read full article
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Read full article
Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
Read full article
Alnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk.
Read full article
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
Read full article
Analysts remain bullish about Alnylam despite its steep sell-off. The competitive landscape for Alnylam is more promising now thanks to two recent developments.
Read full article
Arizona State Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 5.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,025 shares of the biopharmaceutical company's stock after acquiring an additional 2,126 shares during the period. Arizona
Read full article
Concurrent Investment Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 695.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,521 shares of the biopharmaceutical company's stock after purchasing an additional 6,576 shares during the
Read full article
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 10:00 AM ET in New York City A live audio webcast of each pre.
Read full article
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Read full article